ERBB2 and breast cancer: Clinically, in our phase III randomized NEOZOTAC study examining the effect of zolendronic acid (ZA) in addition to neoadjuvant TAC chemotherapy in HER2 negative early breast cancer, ZA did not improve the primary endpoint, pathological complete response (pCR) [23].